Nonsteroidal anti-inflammatory drugs and cancer pain

Area of Science:

• Oncology
• Pain Management
• Pharmacology

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently considered for pain management in cancer patients.
• However, high-quality evidence supporting their efficacy and safety in this population is limited.
• Potential risks associated with NSAID use, such as gastrointestinal and renal complications, require careful consideration.

Purpose of the Study:

• To critically appraise the most recent evidence regarding the use of NSAIDs in managing cancer pain.
• To evaluate the role of NSAIDs in combination with other analgesics and in specific patient subgroups.
• To assess the potential anticancer properties of NSAIDs.

Main Methods:

• Systematic review of recent literature, including Cochrane reviews and retrospective data.
• Analysis of evidence for combined NSAID use with opioids.
• Examination of data on NSAID use in elderly patients nearing end of life.
• Review of studies on NSAIDs post-oncological surgery and their association with anastomotic leaks.
• Consideration of gastroprotection strategies and associated risks.

Main Results:

• Paucity of high-quality evidence for NSAID use in cancer pain.
• Limited evidence for combined NSAIDs and opioids, though some retrospective data suggests benefit.
• Retrospective data indicates reduced NSAID prescribing in elderly patients near end of life without impacting pain relief.
• Systematic review on post-surgical NSAIDs and anastomotic leaks was inconclusive.
• General population studies suggest long-term proton pump inhibitor (PPI) use for gastroprotection carries risks (renal dysfunction, fractures).
• Retrospective data suggests NSAIDs may have a role in cancer risk reduction.

Conclusions:

• NSAID use in cancer pain lacks robust evidence and should be individualized.
• Treatment decisions require a careful balance of potential benefits against risks, including gastrointestinal and renal side effects.
• Ongoing monitoring of efficacy and patient prognosis is crucial for informed prescribing.
• NSAIDs may hold potential in cancer prevention, warranting further investigation.